StockData
Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc. (CRVS) stock

CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$10.17−0.43 (-4.06%)

Close on Nov 17, 2026Market cap $855.51MP/E –Yield –

Corvus Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Corvus Pharmaceuticals's pe ratio was 30.0× on Jan 31, 2022.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2022Jan 31, 202230.0×−10.2
2021Dec 31, 202140.2×–

More Corvus Pharmaceuticals figures

See a number that looks wrong?